Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy

T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes

(2019) Tomasz Kula et al.   CELL

UniProt: the universal protein knowledgebase

(2018) The UniProt Consortium   NUCLEIC ACIDS RESEARCH

An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules

(2018) Jane Harper et al.   PLoS One

T-cell receptor-engineered T cells for cancer treatment: current status and future directions

(2017) Yu Ping et al.   Protein & Cell

Trial Watch: Adoptively transferred cells for anticancer immunotherapy

(2017) Carole Fournier et al.   OncoImmunology

Toward a Shared Vision for Cancer Genomic Data

(2016) Robert L. Grossman et al.   NEW ENGLAND JOURNAL OF MEDICINE

T cell receptor binding affinity governs the functional profile of cancer-specific CD8+T cells

(2015) M. P. Tan et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

(2015) Aaron P Rapoport et al.   NATURE MEDICINE

Deconstructing the Peptide-MHC Specificity of T Cell Recognition

(2014) Michael E. Birnbaum et al.   CELL

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

(2014) P. F. Robbins et al.   CLINICAL CANCER RESEARCH

Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions

(2014) Paul F. Robbins et al.   JOURNAL OF IMMUNOLOGY

Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer

(2014) Sayeema Daudi et al.   PLoS One

Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells

(2014) Giovanna Bossi et al.   OncoImmunology

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

(2013) G. P. Linette et al.   BLOOD

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

(2013) Richard A. Morgan et al.   JOURNAL OF IMMUNOTHERAPY

T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy

(2013) S. Zhong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells

(2013) B. J. Cameron et al.   Science Translational Medicine

MAGE-A antigens as targets in tumour therapy

(2012) David W. Meek et al.   CANCER LETTERS

Different affinity windows for virus and cancer-specific T-cell receptors: Implications for therapeutic strategies

(2012) Milos Aleksic et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

A Single Autoimmune T Cell Receptor Recognizes More Than a Million Different Peptides

(2011) Linda Wooldridge et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

(2011) Paul F. Robbins et al.   JOURNAL OF CLINICAL ONCOLOGY

The biology of cancer testis antigens: Putative function, regulation and therapeutic potential

(2011) Elisabetta Fratta et al.   Molecular Oncology

“Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy

(2010) Federico Garrido et al.   INTERNATIONAL JOURNAL OF CANCER

T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

(2010) Maria R Parkhurst et al.   MOLECULAR THERAPY

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy

(2010) Gavin M Bendle et al.   NATURE MEDICINE

Mixed T cell receptor dimers harbor potentially harmful neoreactivity

(2010) M. M. van Loenen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

(2009) L. A. Johnson et al.   BLOOD

Cancer/testis (CT) antigens: Potential targets for immunotherapy

(2009) Otavia L. Caballero et al.   CANCER SCIENCE